Cascade Prodrug Strengthens Board of Directors
Cascade Prodrug, Inc. is pleased to announce the addition of two esteemed professionals, Manuel (Manny) Litchman, M.D. and Andres Gutierrez, M.D., Ph.D., to its Board of Directors. This strategic move comes as the company enhances its commitment to developing innovative hypoxia-activated therapies for oncology. With their extensive backgrounds, Dr. Litchman and Dr. Gutierrez are well-positioned to guide Cascade into its next phase of growth.
Experience of New Board Members
Dr. Litchman, who has been leading Mustang Bio as President and CEO since April 2017, brings over 30 years of biopharmaceutical experience. His notable career includes previous leadership roles at Arvinas, Inc. and Novartis Pharmaceuticals, where he was instrumental in notable projects including CTL019 (now Kymriah). His vast expertise encompasses areas such as drug development, corporate financing, and the ever-important experience in clinical operations.
Educational Excellence
Dr. Litchman earned his medical degree from the prestigious Yale University School of Medicine. Following this, he completed a rigorous residency in internal medicine and a fellowship in hematology-oncology at New York-Presbyterian Hospital and Weill Cornell Medical Center, laying a strong foundation for his future successes in the field.
The Contributions of Dr. Gutierrez
Joining him is Dr. Andres Gutierrez, who is highly regarded for his extensive expertise spanning over two decades in oncology. His career highlights include significant roles in leading clinical developments and managing large teams across various functions like regulatory affairs, strategy, and fundraising. Previously, he served as Chief Medical Officer for several biotech companies including Ayala, Advaxis, and Oncolytics Biotech.
A Broad Spectrum of Knowledge
Dr. Gutierrez holds both M.D. and Ph.D. degrees and completed his internal medicine residency in Mexico, followed by an esteemed fellowship in Clinical Oncology Research at Hammersmith Hospital in London. His insights into drug efficacy and patient outcomes will be invaluable as Cascade Prodrug seeks to advance its clinical initiatives.
A Statement from Cascade's Leadership
Reacting to the new appointments, Allan Cochrane, President and Co-Founder of Cascade Prodrug, expressed his enthusiasm stating, "Manny and Andres bring a wealth of knowledge in oncology and drug development to our board. Their experience will be critical as we progress with our lead compound CPD100Li into clinical trials." The excitement surrounding their expertise highlights the strategic decisions Cascade is making to ensure effective leadership in its groundbreaking projects.
Looking Forward: The Future of Cascade Prodrug
Dr. Litchman expressed his honor in joining the board at a transformative time for Cascade. He acknowledged the potential of the company's innovative approach to oncology drug delivery and his eagerness to collaborate with existing board members and leadership to accelerate the development of CPD100Li, which is poised for a Phase 1 clinical trial.
Welcoming a New Era
Dr. Gutierrez also shared his anticipation for what lies ahead, stating, "This opportunity aligns perfectly with my commitment to advancing cancer treatments. I look forward to collaborating with Dr. Litchman and the talented team at Cascade to make a significant impact in the field of oncology." Their combined vision and leadership are set to propel Cascade to new heights.
About Cascade Prodrug, Inc.
Cascade Prodrug, Inc. is dedicated to developing hypoxia-activated therapeutics that target one of the most common characteristics of tumor microenvironments. The company's lead candidate, CPD100Li, has shown promising preclinical efficacy across multiple cancer types, including pancreatic, lung, and colon cancers, either alone or in combination with various treatment methodologies.
Contact Information for Cascade Prodrug
For further inquiries or details regarding their innovative research and development, you can reach out to:
Cascade Prodrug, Inc.
Allan Cochrane
President & Co-Founder
Email: allan@cascadeprodrug.com
Eric Malek
Chief Business Officer
Email: eric@cascadeprodrug.com
Frequently Asked Questions
What is the mission of Cascade Prodrug, Inc.?
Cascade Prodrug focuses on developing hypoxia-activated therapies aimed at improving cancer treatments and patient outcomes.
Who are the newly appointed board members?
The new board members are Manuel Litchman, M.D. and Andres Gutierrez, M.D., Ph.D., who bring a wealth of experience in oncology and drug development.
What is the role of CPD100Li?
CPD100Li, Cascade's lead compound, is designed to be highly effective against various cancers by targeting the unique aspects of the tumor microenvironment.
How does Cascade Prodrug aim to advance its therapies?
The company emphasizes innovation and collaboration within its leadership team to expedite the clinical trial process and bring treatments to market.
What previous roles did the new board members hold?
Dr. Litchman was previously the CEO of Mustang Bio, and Dr. Gutierrez has held CMO roles at several biotech firms, leading significant oncology developments.
